News - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

News


Pharmaceutical Technology Europe
Volume 24, Issue 6

News bites

Novartis takes on UK NHS

The UK's National Health System has cut the cost of treating wet age-related macular degeneration (AMD) by prescribing a cheaper drug over a more expensive one. The controversial element is that the cheaper drug isn't licensed for wet AMD, which has prompted anger from Novartis.
http://PharmTech.com/NovartisUK

Merck job cuts

Merck KGaA has revealed further details about its restructuring programme, including plans to eliminate around 580 jobs. A further 750 positions will be transferred from Switzerland to alternative sites mainly in Germany, the US and China. Among other actions, the company will close its Merck Serono headquarters in Geneva.
http://PharmTech.com/Merckcuts

UK anticounterfeiting

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has launched a new anticounterfeiting strategy with the aim of curbing the occurrence of falsified medicines in the county's supply chain. The strategy will focus on prevention, incident management, and investigation of all reports of falsified medicines in the UK.
http://PharmTech.com/UKStrategy

GSK eyes medicines class

GlaxoSmithKline has partnered with the US's Yale university to design a new class of medicines that could be beneficial in areas such as oncology and infection. The collaboration will use proteolysis targeting chimeric molecules, which have the ability to guide proteins to a cell's cleaning mechanism, where they can then be destroyed.
http://PharmTech.com/Class


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology Europe,
Click here